Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …

Background Reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap)
vaccine is recommended in many countries for boosting immunity in adolescents and adults …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …

Pertussis is a highly contagious disease, for which periodic peaks in incidence and an
increasing number of outbreaks have been observed over the last decades. The reduced …

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …

Background In a prospective, randomized pivotal phase III clinical trial, the immunogenicity
and reactogenicity of a tetanus-diphtheria-acellular pertussis vaccine (Tdap) and a tetanus …

Background. The recent introduction of acellular pertussis vaccines (Pa) offers the possibility
of booster doses in older children and adults. This can be conveniently accomplished by …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …